<DOC>
	<DOCNO>NCT00521989</DOCNO>
	<brief_summary>CRx-102 synergistic combination drug candidate contain cardiovascular drug dipyridamole low dose glucocorticoid prednisolone . CRx-102 believe work novel mechanism action dipyridamole selectively amplify anti-inflammatory immunomodulatory activity glucocorticoid without replicate dose-dependent adverse effect . CRx-102 associated clinical benefit proof concept study subject hand OA RA . This first study explore efficacy CRx-102 knee OA . It consider dose-finding study also compare potential benefit CRx-102 treatment prednisolone administer alone placebo indication .</brief_summary>
	<brief_title>CRx-102 Osteoarthritis Multicenter Evaluation Trial</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Dipyridamole</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Subject must voluntarily give write informed consent Subject must ≥ 40 year age Knee pain least 6 month require NSAIDs Coxibs analgesia majority day ( ≥ 15 day ) precede month WOMAC pain score walk flat surface ( question # 1 ) 3080 mm Screening least 10 mm increase follow NSAID Coxib discontinuation Screening period Radiographic evidence knee OA ( KellgrenLawrence grade 2 3 ) Functional class I , II , III accord American Rheumatism Association Subject willing take multivitamin equivalent least 400 IU vitamin D equivalent least 1000 mg elemental calcium daily Predominant patellofemoral disease clinically significant trauma index knee History clinically significant ( determined Investigator ) cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , osteoporotic and/or major disease History malignancy within past 10 year ( except excise treat basal cell few 3 squamous cell skin carcinoma ) History lymphoma chronic leukemia Moles lesion currently undiagnosed , suspicious malignancy Surgery within previous 3 month ( except minor dental , and/or cosmetic procedure ) History drug alcohol abuse ( define Investigator ) History bleed disorder History GI bleed within 5 year Screening History severe migraine headache History glaucoma Visually compromise cataract Active diabetic retinopathy History osteoporotic fracture History opportunistic infection Serious local infection ( e.g. , cellulitis , abscess ) systemic infection ( e.g. , septicemia ) within 3 month prior Screening Fever symptomatic viral bacterial infection within 2 week prior Screening Positive hepatitis C ( HCV ) antibody Positive hepatitis B surface antigen ( HBsAg ) Known positive history human immunodeficiency virus ( HIV ) antibody Surgery index knee within 1 year Screening History hypersensitivity steroid dipyridamole Treatment oral , intramuscular , intravenous glucocorticoid within 6 week prior Screening ; intraarticular glucocorticoid within 10 week prior Screening ; inhale glucocorticoid permit Treatment injectable hyaluronic acid within 3 month Screening Treatment another investigational drug , investigational device , approve therapy investigational use within 30 day prior Screening Treatment NSAIDs ( oral topical ) , Coxibs topical capsaicin Treatment anticoagulant include : dipyridamole , warfarin , clopidogrel , ticlopidine , ASA &gt; 81 mg per day Treatment concomitant medication stable dose least 28 day prior Screening Treatment osteoporosis bisphosphonates ( e.g. , Fosamax® , Actonel® ) , teriparatide ( e.g. , Forteo® ) , calcitonin ( e.g. , Miacalcin , Calcimar ) must stable dosage least 3 month prior Screening ALT AST laboratory value &gt; 1.5 X ULN HgbA1c value &gt; 7.0 % Current enrollment study investigational drug device Female subject pregnant lactating Unwilling unable comply requirement protocol , include presence condition ( physical , mental , social ) likely affect subject 's return followup visit schedule Other unspecified reason , opinion Investigator sponsor make subject unsuitable enrollment</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Knee</keyword>
	<keyword>CRx-102</keyword>
	<keyword>prednisolone</keyword>
	<keyword>dipyridamole</keyword>
	<keyword>CombinatoRx</keyword>
	<keyword>WOMAC</keyword>
</DOC>